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ABSTRACT
Exosomes are cell derived lipid nanoparticle with a size of 30–100 nm in diameter, found in almost all biological fluids. 
The composition of the exosomes is mainly lipid, proteins, RNA, DNA, and non-coding RNAs. Currently, most available 
methods and commercial kits for exosomal-RNA (Exo-RNA) isolation have limitations and shortcomings. Small start-
ing volume of exosomes and the use of extraction/filtration columns results usually insufficient yield of exosomal RNA 
after isolation. The majority of RNA contained in purified exosomes range in size from 15–500 nucleotides. Some RNA 
isolation kits are well suited for small RNA transcripts isolation but larger mRNA transcripts are hard to detect. For all of 
the kits, the cost prize per sample analyzed is very high. Our current method provides a novel way for direct conversion 
of exosomes into cDNA synthesis (Exo-cDNA) and subsequent gene detection by polymerase chain reaction (PCR). 
This method has several advantages compared to established available kits. No extraction column is utilized in this 
procedure which means total recovery of exosomal RNA with maximal yield. In addition, this method is fast and uses 
a minimal amount of lab supplies, thereby reducing the overall working costs. Our findings suggest that direct conver-
sion of exosomes into cDNA and subsequent gene amplification by two step PCR is a most efficient and reproducible 
technique. This novel method can be applied to and is useful to advance molecular research of exosomes by solving 
the problem of low molecular yields.
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INTRODUCTION
Exosomes are spherical (lipid bilayer) nanoparticles secreted by 
almost all cell types which contain an endomembrane system. Exosomes 
are composed of proteins, DNA, mRNA and non-coding RNA [1-2]. 
The size of exosomes range between 30–100 nm, and they originated 
from the cytoplasm of the cell by inward budding of multi-vesicular 
bodies [3]. Exosomes are abundantly found in bio-fluids such as saliva, 
serum, urine, breast milk, cerebrospinal fluid, and amniotic fluid [4-7]. In 
addition, exosomes have been isolated in vitro from conditioned medium 
(CM) of cultured cell lines [8]. In biomedical research, understanding 
the nature of exosomes is especially important to facilitate early diag-
nosis, early relapse, risk stratification, and targeting of the disease by 
real-time exosomal biomarker studies. However, progress in exosomal 
biomedical research is still facing some hurdles to overcome. Although 
there are several commercially available methods for exosomal RNA 
isolation, most of them have some limitations. A ready-made pre-designed 
manufactured exosome isolation column can usual process up to 4.0 ml 
of serum, but processing smaller volumes of less than 1.0 ml of serum 
yields poor quality of exosomal RNA [9]. Processing of higher sample 
volume columns is also more expensive. In addition, the multi-step 
processing of the exosome samples first through the isolation column, 
followed by several washing steps to retrieve the exosomal RNA, results 
in loss of exosomal RNA. Other exosomal RNA isolation kits are based 
on the acid-phenol: chloroform extraction method to provide a robust 
front-end RNA extraction followed by a final RNA purification over a 
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glass-fiber filter by addition of ethanol to the columns, to immobilize 
the isolated RNA. The filter is then washed for RNA elution but again, 
the step wise filtration/washing procedure results in loss of RNA yields 
[10]. Investigators in exosome research are still juggling for the optimal 
exosomal RNA extraction method that results in greater yields and higher 
quality of RNA from the smaller sample volume. There is a dire need 
to improve the sensitivity of existing exosomal RNA isolation methods 
while maintaining minimal usage of the already spare exosomal starting 
volumes. Haque et al. had previously described a RNA isolation method 
from single cells for detection of p53 mRNA transcript. In this study, single 
cells were sorted by flow cytometry into polymerase chain reaction (PCR) 
tubes, and then lysed by adding lysing buffer in the same PCR tube, with 
subsequent direct conversion of isolated RNA into cDNA. The p53 mRNA 
expression was confirmed by using the obtained cDNA template in a two 
steps PCR [11]. Since p53 is present at low copy number in the cell, 
two rounds of PCR amplification were necessary for detection in this 
so-called two step PCR method. Based on the successful implementation 
of the two step PCR method for RNA isolation from a single cell (which 
implies a very low RNA starting volume), we applied this method for 
exosomal RNA isolation as well. Extrapolation of the single cell RNA 
isolation method to exosomal research might have been a far stretch if 
we only compare the diameter size of a single cell (8–12 µm) with the 
diameter size of an exosome (30–100 nm) [12]. In addition, the copy 
number of mRNA transcript carrying capacity is also different in cells 
and exosomes. However, since purified exosomes are pooled together 
after isolation from body fluid, serum or CM and the exosomal start 
sample for RNA isolation is quantitated by protein content measuring 
(NanoDrop), we thought it might be worth trying.
This study focuses on the method of direct conversion of exosomes 
into cDNA and gene amplification by PCR. It has several advantages 
such as: (1) no use of an extraction column resulting in higher yields 
of exosomal RNA recovery; (2) smaller starting volume of exosomes 
is sufficient for the procedure; (3) less time consuming than existing 
methods; and (4) cheaper than commercially available kits and meth-
ods. Making this reproducible method available for widespread use in 
the scientific exosome research community might hopefully at least 
alleviate one of the hurdles in this field.
MATERIAL AND METHODS
Cell lines and cell culture
The acute lymphatic leukemia (ALL) cell lines SUP-B15 (cat. # 
ATCC® CRL-1929™), and JM1 cells (cat. # ATCC® CRL-10423™) 
were purchased from ATCC. SUP-B15 cells were cultured in Iscove’s 
Modified Dulbecco’s Medium (IMDM), supplemented with 1.5 g/L 
sodium bicarbonate, 0.05 mM β-mercaptoethanol, 20% fetal bovine 
serum (not heat inactivated), and 1× Penicillin-Streptomycin. JM1 
cells were expanded and cultured in IMDM supplemented with 0.05 
mM β-mercaptoethanol, 10% FBS, and 1× Penicillin-Streptomycin. 
Normal B-cell line cells CL01 (Chiorazzi lab, The Feinstein Institute) 
were expanded and cultured in RPMI-1640 supplemented with 10% 
FBS, and 1× Penicillin-Streptomycin. All cell lines were incubated in 
a humidified incubator at 37°C with 5% CO2. Solid tumors cell lines 
such as HepG2 cells (Hepatocellular carcinoma cell line), HeLa cells 
(Cervical cancer), and SiHa cells (Squamous cell carcinoma) were 
placed in tissue culture to isolate exosomes from conditioned medium.
Collection of human serum
Healthy donor (HD) and ALL patients’ serum samples were obtained 
after informed consent according to Institutional Review Board (IRB) 
approved protocol. Serum was isolated from whole blood by the stan-
dard method of centrifugation. Age and gender of the human samples 
cannot be released for Health Insurance Portability and Accountability 
Act (HIPAA) protection as per institutional IRB guidelines.
Exosome isolation by ultracentrifugation
Purification of exosomes was carried out by ultracentrifugation 
method [8]. In brief; CM from cultured cells or human serum was 
subjected to centrifugation for 10 min at 300× g. Supernatant was col-
lected and centrifuged for 10 min at 2000× g. Again, supernatant was 
collected and centrifuged for 30 min at 10000× g. Then supernatant was 
ultra-centrifuged for 120 min at 100000× g. Pellets containing isolated 
exosomes were re-suspended in phosphate buffered saline (PBS) and 
ultra-centrifuged for an additional 120 min at 100000× g. Exosomes 
containing pellets were harvested and reconstituted in 500 µl PBS. 
Each centrifugation step was carried out at 4°C. The protein content 
of the exosomes was determined by a BCA protein assay kit (Bio-Rad) 
and NanoDrop ND1000 spectrophotometer. Isolated exosomes from 
CM (Exo-CM) and serum (Exo-serum) were aliquoted and stored at 
−80°C for further usage.
Exosome isolation by column based kit
Alternatively, exosomes of human serum and conditioned medium 
of cells lines were isolated by a column based kit (cat. # 76064, Qiagen) 
as per manufacturer protocol.
Protocol for Exo-cDNA (Exosomes into cDNA)
Details of the composition of buffers A, B and C are listed in Table 1. 
The source of reagents is mentioned below.
Source of enzymes and inhibitors
RNase inhibitor (4 unit/µl) (cat. # 1055213, Qiagen), rRNasin RNase 
inhibitor (40 U/µl) (cat. # N251B, Promega), RT-Superscript III (200 
U/µl) (cat. # 18080-044, Invitrogen), random hexamer primers (cat. # 
SO142, Thermo Fisher Scientific).
Protocol steps
1. Take purified exosomes (40–200 µg protein in 10–12 µl 
volume PBS) into PCR tubes (USA Scientific).
2. Add buffer A (3.6 µl/reaction) into the same tube, mix by 
gentle tapping and place on dry ice for 5 min.
3. Transfer the PCR tubes from dry ice to wet ice and add 
buffer B (3.5 µl/reaction), mix well by gentle tapping and 
incubate for 5 min at 65°C.
4. Centrifuge (1000–1500 rpm for 10–20 s) the PCR tubes 
to collect samples at the bottom then keep samples on ice.
5. Add buffer C (7.0 µl/reaction) into the same tube, mix by 
gentle tapping and centrifuge to collect sample at the bottom.
6. Place PCR tubes with samples into thermo-cycler (Gene 
Amp PCR system, Applied Biosystems) programmed as 
follows: Reverse transcriptase (RT) steps are 42°C for 5 
min, 25°C for 10 min, 40°C for 60 min, 70°C for 10 min 
(denaturation step).
7. Centrifuge the PCR tubes to collect samples at the bottom 
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of the tube and store the samples containing the cDNA 
templates at −20°C for further use.
Table 1. Composition of buffers A, B and C.
Buffer A 1 reaction
10× PBS 0.25 µl
H2O 2.50 µl
DTT (100 mM) 0.4 µl
rRNasin Rnase inhibitor (Promega) 0.2 µl
RNase inhibitor (4 unit/µl, Qiagen) 0.25 µl
Total 3.6 µl
Buffer B 1 reaction
Random primers (300 ng/ µl) 0.5 µl
NP-40 (10%) 0.5 µl
H2O 2.25 µl
PrimRNAse inhibitor (Qiagen) 0.25 µl
Total 3.5 µl
Buffer C 1 reaction
5× first strand buffer 3 µl
H2O 1.0 µl
DTT (100 mM) 1.0 µl
dNTPs (10 mM) 1.25 µl
rRNasin RNase inhibitor (40 unit/ml, 
Promega)
0.25 µl
RNase inhibitor (4 unit/µl, Qiagen) 0.25 µl
RT-SuperScript III (200 U/µl) 0.25 µl
Total 7 µl
Gene amplification utilizing Exo-cDNA as template by 
two steps PCR
Gene amplification of β-actin, HLA-DR, CXCR4 and CD34 was 
carried out by PCR. For PCR amplification, a total reaction volume of 
30 µl was obtained by mixing 2.0 µl of Exo-cDNA. Briefly, first round 
of PCR was carried out using AccuPrime™ Pfx DNA Polymerase (cat. 
# 12344024, Thermo Fisher Scientific) (1 unit/reaction in 30.0 µl final 
volume). Second round of PCR was carried out using Ampli Taq Gold 
(1 unit/reaction in 30.0 µl final volume) (Applied Biosystems, Roche, 
NJ). Both cycles of PCR ran under the following cycling conditions: 
denaturation at 95°C for 30 s, annealing at 56°C–60°C for 60 s, and 
extension step at 72°C for 60 s for 35 cycles. Cell-cDNA (control) and 
Exo-cDNA (2 µl) were used as template for the first round of PCR. For 
the second round of PCR, 1–2.0 µl of the PCR amplicon of the first 
round was utilized as template, AmpliTaq Gold (Applied Biosystems, 
Roche, NJ) was added to a final volume of 30 µl and the thermo-cycler 
was programmed in the same way as for the first round of PCR. Primer 
sequence, gene accession numbers, annealing temperature, and amplicon 
size are listed in Table 2.
Agarose gel electrophoresis
PCR amplified products were analyzed by agarose gel electrophoresis 
as follows: 1.5% agarose gel (cat. # CA3510-8, Denville Scientific, Inc.). 
Gel was prepared in 1× Tris-borate-EDTA buffer (cat. # 28355, Thermo 
Fisher Scientific). SYBR Safe (cat. # S33102, Invitrogen) was added 
to the agarose gel before polymerization. Agarose gel was loaded with 
5.0 µl of each PCR amplicon product mixed with 6× loading dye (cat. 
# R0611, Crystalgen) and ran for 20–25 min at 200 V. Each agarose gel 
was loaded with standard 100 base pair markers/ladder (cat. # 65-0321, 
Crystalgen). The gel was exposed and captured for imaging using a 
Bio-Rad gel documentation system (Bio-Rad, Hercules, California). 
Intensity/densitometry of agarose gel band was measured by Image J.
Cellular RNA extraction and cDNA preparation (used as 
controls)
Total RNA was extracted from SUP-B15, JM1, and CL-01 cells by 
Trizol reagent method (Invitrogen). Quality and quantity of RNA was 
analyzed by NanoDrop ND1000 spectrophotometer. Isolated cellular 
RNA (2–5 µg) was used for cDNA synthesis by qPCR by adding Oli-
go-dT primers (Invitrogen) and M-MLV reverse transcriptase (cat. # 
28025-013, Invitrogen) as per manufacturer's protocol.
Protein expression by Western blot
Cell lysates of cultured cells (CL-01, SUP-B15, etc.) and exosomal 
lysate of exosomes were prepared in RIPA buffer (cat. # RO278-50 ml, 
Sigma-Aldrich) supplemented with protease and phosphatase inhibitor 
(cat. # PI 78441, Thermo Fisher Scientific). Protein was estimated by 
Pierce BCA protein assay kit (cat. # 23227, Thermo Fisher Scientific). 
Equal amounts of protein (15–20 µg) were loaded for electrophoresis 
on 4 to 15% SDS-PAGE (cat. # 456-1083, Bio-Rad). Electrophoresed 
proteins were transferred to an immune-blot polyvinylidene fluoride 
membrane (Bio-Rad). Membranes were blocked with PBS-Tween (0.1%) 
with 5% non-fat milk for 1 h and incubated with primary antibodies 
overnight at 4°C, followed by HRP-conjugated secondary antibody 
(dilution 1:2000; Santa Cruz Biotechnology), and then immunoblots 
were developed with enhanced chemiluminescent solution (Pierce, 
Rockford, IL). Primary antibodies calnexin (cat# sc-23954, Santa Cruz 
Biotech) and CD63 (cat. # 556019, BD Pharmingen) were used at 
1:1000 dilutions. The blots were developed with a chemiluminescence 
detection kit (Pierce) and exposed to X-ray film (Eastman Kodak Co., 
Rochester, NY).
RESULTS
Characterization of exosomes by western blot and 
NanoSight (NTA) analysis
Exosomes were purified from both human serum and cell cultured 
supernatants/ CM by ultra-centrifugation. We checked expression of 
CD63 (exosome positive marker) and calnexin (exosome negative protein 
marker). Western blot shows that human Exo-CM and Exo-serum are 
negative for calnexin and positive for CD63 expression (Fig. 1A) which 
confirms the identity of the exosomes. We also examined and confirmed 
the size of the exosomes by nano-tracking analysis (NTA, Malvern). 
NTA confirms the correct size of the isolated exosomes (50–200 nm) 
(Fig. 1B), as well as provides an image of exosomes (Fig. 1C). As 
illustrated in the graph of Fig. 1B, it appears that 90% of exosomes 
are within the 50–100 nm diameter which is within the optimal range 
of size for exosomes and confirms their homogeneity.
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Table 2. Sequence of human primers.
Gene Accession number Sequences Annealing temperature Amplicon size
CXCR4 AY242129.1 For*: 5'-AATGAGGCCACAACAAACATCACA-3’
Rev*: 5‘-ATCCAGACGCCAACATAGAC-3'
58°C 464 bp
CD34 M81104.1 For: 5‘-AATGAGGCCACAACAAACATCACA-3'
Rev: 5‘-CTGTCCTTCTTAACCTCCGCACAGC-3'
56°C 380 bp
HLA-DR K01171.1 For: 5‘-ATCATGACAAAGCGCTCCAACTAT-3'
Rev: 5‘-GATGCCCACCAGACCCACAG-3'
60°C 404 bp
β-actin NM_001101.4 For: 5‘-GTCCTCTCCCAAGTCCACACA-3'
Rev: 5‘-CTGGTCTCAAGTCAGTGTACAGGTAA-3'
60°C 240 bp
*For, forward primer, Rev, reverse primer.
Figure 1. Characterization of purified exosomes. A. Western blot analysis for CD63 and calnexin of Exo-CM and Exo-serum. B. Nano Track Analysis 
(NTA) of isolated serum exosomes. Exosomal identity was confirmed for size and homogeneity. C. NTA exosomes imaging with representative picture 
of exosomes.
Amplification of exosomal β-actin by two step PCR
To apply the single cell RNA isolation and two step PCR method in 
exosomes, we first tested amplification of the endogenous housekeeping 
gene β-actin by two steps PCR (Fig. 2). Exo-cDNA synthesized by 
direct conversion from 14–43 µg Exo-serum failed to amplify β-actin 
in the first round of PCR (Fig. 2A, upper panel). It was not until after a 
second round of PCR that we were able to detect a band corresponding 
to the amplified β-actin Exo-cDNA (Fig. 2A, lower panel). Exo-cDNA 
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synthesized from 37–222 µg Exo-CM of the JM1 cell line successfully 
amplified β-actin in first round of PCR (Fig. 2C, upper panel) with con-
firmation in a second round of PCR (Fig. 2C, lower panel). The PCR 
band intensity data by Image J densitometry identified the concentration 
dependent increase in PCR products (Fig. 2B-2D).
Amplification of exosomal CXCR4 by two step PCR
Next, we chose to use the CXCR4 gene for further verification of 
this method (Fig. 3). Exo-cDNA synthesized from 14–43 µg Exo-se-
rum failed to amplify CXCR4 in a first round of PCR (Fig. 3A, upper 
panel). Detectable amplification of CXCR4 expression was found after 
a second round of PCR (Fig. 3A, lower panel). Exo-cDNA synthesized 
from 37–222 µg Exo-CM (JM1) successfully amplified CXCR4 in first 
round of PCR (Fig. 3C, upper panel) and second round of PCR also 
showed CXCR4 amplification (Fig. 3C, lower panel). It appears that 
CXCR4 is abundantly expressed in JM1 cell line-derived exosomes. 
The PCR band intensity data by Image J densitometry identified the 
concentration dependent increase in PCR products (Fig. 3B-3D).
Figure 2. Amplification of exosomal β-actin by two-step PCR. Agarose gels were ran after first and second round of PCR amplification as shown in 
upper and lower panel respectively. A. Exo-serum cDNA (ALL patient serum) failed to amplify sufficient β-actin product after first round of PCR. B. PCR 
band intensity of (Fig. 2A) measured by image J densitometry. C. Exo-CM cDNA (JM1 cell line) did show a detectable amount of β-actin amplicon after 
first round of PCR. D. PCR band intensity of (Fig. 2C) measured by image J densitometry. Both Exo-serum cDNA and Exo-CM cDNA β-actin amplicons 
were detected after second round of PCR. A minimal exosomal amount of 14–37 µg was sufficient to obtain a signal only after two rounds of PCR. NC: 
negative control, no template added; PC: positive control, cell-cDNA used as template.
Two step PCR in Exo-cDNA and Cell-cDNA of parental 
cells
Exosomal RNA content is derived from the parental cell of origin. 
Therefore, it would make sense to test the two step PCR method on 
Exo-cDNA and compare it to Cell-cDNA analysis derived from the 
parental cell. Both templates should show amplification of the tested 
genes if exosomal content is indeed derived from the parent cell.
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Figure 3. Amplification of exosomal CXCR4 by two step PCR. Agarose gels were ran after first and second round of PCR amplification as demon-
strated in upper and lower panel respectively. A. Exo-serum cDNA (ALL patient serum) failed to amplify sufficient CXCR4 product after first round of 
PCR. B. PCR band intensity of (Fig. 3A) measured by image J densitometry. C. Exo-CM cDNA (JM1 cell line) did show a detectable amount of CXCR4 
amplicon after first round of PCR. D. PCR band intensity of (Fig. 3C) measured by image J densitometry. Both Exo-serum cDNA and Exo-CM cDNA 
CXCR4 amplicons were detected after second round of PCR. A minimal exosomal amount of 14–37 µg was sufficient to obtain a signal only after two 
rounds of PCR. NC: negative control, no template added; PC: positive control, cell-cDNA used as template.
Figure 4. Schematic illustration of two step PCR in Cell-cDNA and Exo-cDNA of parental cells. A. Total RNA was isolated from parental cells by 
RNeasy Mini kit and Cell-cDNA was prepared by M-MLV reverse transcriptase kit (Qiagen). B. Purified exosomes were directly converted into Exo-cDNA 
by the direct conversion method (details are in material and method section).
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Total RNA was isolated from cultured cells and Cell-cDNA was 
prepared by M-MLV reverse transcriptase kit (Fig. 4A). In contrast, 
purified exosomes of CM of the same cell line source in culture were 
harvested and processed according to the described direct conversion 
method. Briefly, after lysis by addition of a mild detergent, cDNA 
synthesis buffer and RT enzymes were added in the same PCR tube 
to achieve conversion of RNA into the cDNA (Exo-cDNA) (Fig. 4B).
Amplification of HLA-DR and CD34 in Exo-cDNA com-
pared to Cell-cDNA
Three different cell lines (JM1, SUP-B15, and CL-01) were grown 
in tissue culture for harvesting of Cell-cDNA and Exo-cDNA of CM. 
HLA-DR and CD34 are both clinically used as markers for ALL cells; 
subsequently, Cell-cDNA and Exo-cDNA (2.0 µl) of ALL cell lines JM1 
and SUP-B15 were compared as a template for amplification of HLA-DR 
and CD34 by two step PCR. CL-01 cells (B-cell line) do not express 
CD34 and was used as negative control (Fig. 5). In the first round of 
PCR for the HLA-DR gene, Cell-cDNA produced detectable amount of 
HLA-DR product but Exo-cDNA failed to amplify detectable amount of 
HLA-DR product on an agarose gel (Fig. 5A, upper panel). After a second 
round of PCR, both Cell-cDNA and Exo-cDNA produced detectable 
amount of HLA-DR product on an agarose gel (Fig. 5A, lower panel). 
The same pattern repeated itself for CD34 amplification: after the first 
round of PCR, Cell-cDNA of JM1 and SUP-B15 produced detectable 
amount of CD34 while Exo-cDNA did not amplify detectable levels 
(Fig. 5B, upper panel). However, after the second round of PCR, both 
Cell-cDNA and Exo-cDNA of JM1 and SUP-B15 produced detectable 
amount of CD34 copies while both cell-cDNA and Exo-cDNA derived 
from CL-01 cells remained negative for CD34 expression as expected 
(Fig. 5B, lower panel). Housekeeping gene β-actin was used as control 
for quality confirmation of Cell-cDNA and Exo-cDNA.
Exo-UC and Exo-Col purified exosomes converted into 
Exo-cDNA for gene amplification
To test whether our method works independently of how exosomes 
are isolated, exosomes were isolated by either ultracentrifugation (Exo-
UC) or column-based commercial kit method (Exo-Col). No difference 
was identified between the two isolation methods which is useful when 
sensitivity is required with a low volume of samples. Both sources of 
purified exosomes were converted into the Exo-cDNA. Amplification 
of b-actin was carried out by PCR, following PCR product electro-
phoresed on agarose gel as demonstrated (Fig. 6A). In order to ensure 
the robustness of this method for multiple cell lines, we tested our 
protocol on a small panel of other cancers than leukemia. Exosomes 
were derived from the conditioned medium of three solid tumors cell 
lines (HepG2: hepatocellular carcinoma, HeLa: cervical carcinoma, 
and SiHa: squamous cell lung carcinoma) by both isolation methods 
Exo-UC and Exo-Col. Exo-cDNA was prepared from both exosomes 
source followed by PCR for β-actin amplification (Fig. 6B). Both Exo-
UC and Exo-Col showed similar results confirming consistency and 
reproducibility of the method in other disease settings as well.
Figure 5. Amplification of HLA-DR and CD34 in Cell-cDNA compared to Exo-cDNA. Agarose gels were ran after first and second round of PCR 
amplification as shown in upper and lower panel respectively. A and B. Cell-cDNA for HLA-DR and CD34 amplified by a first round of PCR already in 
leukemia cell lines JM1 and SUP-B15, but CL-01 (B-cells) Cell-cDNA and Exo-cDNA remained negative for CD34 as expected. Exo-cDNA obtained from 
CM of leukemia cell lines only amplified HLA-DR and CD34 after a second round of PCR (β-actin housekeeping gene as quality control).
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We tested our novel method in exosomes derived from both leukemia 
cell lines as well as solid tumors cell lines as mentioned in Table 3. We 
also tested within serum derived exosomes in 14 individuals (including 
healthy donors, leukemia diagnosed patients and relapsed patients) as 
listed in Table 4.
Table 3. List of 6 cell lines used as source for exosome isolation.
SN Exosomes-derived from cell lines Cell line types Experiment (n)
1 JM1 ALL B cells 4
2 SUP-B15 ALL B cells 4
3 CL-01 Normal B cells 4
4 K-562 CML 1
5 HepG2 Hepatocellular carcinoma 1
6 HeLa Cervical cancer 1
7 SiHa Squamous cell carcinoma 1
Figure 6. Exo-UC and Exo-Col purified exosomes converted into Exo-cDNA for gene amplification. A. Exosomes isolation from healthy donor 
serum samples by ultracentrifugation method (Exo-UC) and column-based commercial kit (Exo-Col) both converted into Exo-cDNA. PCR was carried 
out to amplify β-actin as shown on agarose electrophoresis. B. Exosomes were derived from the conditioned medium of three solid tumors cell lines 
(HepG2, HeLa, and SiHa) by both isolation methods Exo-UC and Exo-Col. Exo-cDNA was prepared from both exosomes sources and PCR was carried 
out to amplify β-actin as demonstrated on agarose gel image. NC: negative control, no template added; PC: positive control, cell-cDNA used as template.
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Figure 7. Schematic illustration of concept. A. Schmeatic diagram explains concept of the novel method, briefly intact exosomes memebrane were 
lysed by the addition of mild detergent which provides chance to access exosomal RNA for the conversion into cDNA (Exo-cDNA). B. Schmeatic diagram 
orients the steps of the protocol. Purified exosomes were taken into a tube and buffers A, B, C, were added into the same tube resulting Exo-cDNA as 
final outcome. 
Table 4. List of serum samples as source for exosomes isolation.
SN Serum samples for exosomes Experiment (n)
1 HD77 serum 3
2 HD78 serum 2
3 HD79 serum 2
4 HD80 serum 2
5 P-ALL25 serum (PB)           D1 = Dx 1
6 P-ALL25 serum (BM)          D1 = Dx 1
7 P-ALL24 serum (PB)          second remission 1
8 P-ALL24 serum (PB)          relapse D1 1
9 P-ALL14C serum (PB)        second remission 1
10 P-ALL14c serum (PB)         relapse D1 1
11 P-ALL01 serum D1(PB)      D1 = Dx 1
12 P-ALL01 serum D29 (PB)   first remission 1
13 P-ALL05 serum (PB)           D1 = Dx 1
14 P-ALL02 serum (PB)           D1 = Dx 1
DISCUSSION
The structural nature of exosomes consists of a lipid bilayer sur-
rounding the nano-sized particle. In this method, exosomes are treated 
with a mild detergent resulting in increased porosity of the exosomal 
membrane or exosomal membrane lysis. As a result, the exosomal content 
becomes available to interact directly with the reagents of the cDNA 
synthesis cocktail. All the RNA content gets converted into cDNA in 
the same tube at the same time (Fig. 7, panel A). Furthermore, we have 
successfully tested the Exo-cDNA obtained by this direct conversion 
method for downstream molecular analysis by nucleotide sequencing 
chromatogram (preliminary results—data not shown).
Exosomal RNA and DNA quantitation is emerging as a key in molec-
ular diagnostics for biomarker development in pathological conditions, 
including cancer [13,14]. We have developed a novel method which 
allows for greater yields of RNA conversion to cDNA followed by two 
step PCR, resulting in enhanced sensitivity for detection of exosomal 
RNA. So far, existing methods involve first multi-step isolation of 
exosomal RNA (resulting in product loss) followed by conversion of 
exosomal RNA into the cDNA. Our current method is more compact and 
differs from other methods in that exosomes are lysed by mild detergent 
allowing for conversion of all RNA content directly into cDNA in the 
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same tube in one single step. Utilizing this Exo-cDNA as a template, 
primer specific different genes such as β-actin, CXCR4, CD34, and 
HLA-DR were amplified by two step PCR. Exo-cDNA derived after 
direct conversion of RNA of exosomes at a minimal amount of 7–43 µg 
protein content did not yield a detectable band of amplicon after the first 
round of PCR. Only after a second round of PCR were we able to detect 
β-actin and CXCR bands on an agarose gel. When higher amounts of 
exosomes (37–222 µg) were converted into Exo-cDNA, a first round 
of PCR was efficient enough to amplify β-actin and CXCR expression 
on an agarose gel. A second round of PCR only showed more abundant 
amplification of both genes. The sensitivity of PCR amplification de-
pends on the initial exosome amount taken for cDNA synthesis. Based 
on our findings, the lower amount of initial exosomes quantity (ranging 
from 7–40 µg) was only able to produce amplification after two rounds 
of PCR while higher amounts of exosomal starting quantity (ranging 
from 40–222 µg) showed abundant amplification already after the first 
round of PCR. Detection of different exosomal RNA content depends 
on the basal expression level of specific RNA in different cell types. 
Some RNA transcripts are abundantly expressed while some shows 
extremely low expression/copy number in nature within single cells 
[15]. Moreover, detection and quantification of any specific mRNA 
transcript from exosomes depends on the molecular signature of the 
parental cell from which exosomes are derived. As such, exosomes 
represent the fingerprint of the parent cells [12,16]. Stevanato et al. 
described that only 1/10th of parental cell miRNA gets transferred to 
their exosomal offspring, e.g., if a single cell has 100 copies of miRNA, 
than exosomes derived from this parent cell will contain 10 copies of 
miRNA [17]. This explains how challenging the task is to detect and 
quantitate exosomal RNA as bio-markers in normal and pathological 
cells because of the lower copy numbers present in exosomes. Stoichi-
ometry of the transfer of RNA from the parental cell to the exosomes 
is poorly investigated, but we have evidence that transfer of parental 
RNA to the exosomal RNA varies from 1/5th to 1/15th. This mRNA 
transfer from parent cell to exosomes depends on the type of mRNA, 
but the exact mechanism is not fully understood (Haque S and Vaiselbuh 
S, unpublished data). In this study, we have tested and compared by 
semi-quantitative two steps PCR, amplification of HLA-DR and CD34 
expression in Cell-cDNA and Exo-cDNA. Interestingly, both cDNA 
templates utilized and produced detectable amount of PCR product on 
agarose gel at the second round of PCR. This shows that, despite of 
a low copy number of mRNA transcript present in exosomes, cDNA 
amplicons are detectable using this novel and sensitive method of direct 
conversion followed by two steps PCR.
In conclusion, we have developed a scalable and cost-effective method 
for the rapid isolation and quantitation of all RNA content present in 
exosomes, regardless of size, which is applicable to small amounts of 
exosomal starting material. This novel method may open the door to 
exploration of the nature and function of the complex mixture of RNA 
present in exosomes. This method represents a major breakthrough for 
the potential usage of exosomes in molecular diagnostics.
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